全文获取类型
收费全文 | 8539篇 |
免费 | 670篇 |
国内免费 | 40篇 |
专业分类
耳鼻咽喉 | 69篇 |
儿科学 | 234篇 |
妇产科学 | 211篇 |
基础医学 | 1069篇 |
口腔科学 | 98篇 |
临床医学 | 994篇 |
内科学 | 1621篇 |
皮肤病学 | 181篇 |
神经病学 | 948篇 |
特种医学 | 209篇 |
外科学 | 1176篇 |
综合类 | 96篇 |
一般理论 | 9篇 |
预防医学 | 886篇 |
眼科学 | 163篇 |
药学 | 639篇 |
中国医学 | 7篇 |
肿瘤学 | 639篇 |
出版年
2024年 | 17篇 |
2023年 | 154篇 |
2022年 | 196篇 |
2021年 | 435篇 |
2020年 | 227篇 |
2019年 | 347篇 |
2018年 | 357篇 |
2017年 | 250篇 |
2016年 | 301篇 |
2015年 | 316篇 |
2014年 | 385篇 |
2013年 | 470篇 |
2012年 | 723篇 |
2011年 | 716篇 |
2010年 | 343篇 |
2009年 | 323篇 |
2008年 | 501篇 |
2007年 | 486篇 |
2006年 | 476篇 |
2005年 | 395篇 |
2004年 | 333篇 |
2003年 | 278篇 |
2002年 | 239篇 |
2001年 | 72篇 |
2000年 | 86篇 |
1999年 | 46篇 |
1998年 | 45篇 |
1997年 | 37篇 |
1996年 | 27篇 |
1995年 | 22篇 |
1994年 | 31篇 |
1993年 | 18篇 |
1992年 | 67篇 |
1991年 | 55篇 |
1990年 | 48篇 |
1989年 | 40篇 |
1988年 | 24篇 |
1987年 | 22篇 |
1986年 | 35篇 |
1985年 | 29篇 |
1984年 | 27篇 |
1983年 | 27篇 |
1982年 | 16篇 |
1980年 | 14篇 |
1979年 | 16篇 |
1978年 | 14篇 |
1977年 | 14篇 |
1975年 | 13篇 |
1974年 | 24篇 |
1967年 | 14篇 |
排序方式: 共有9249条查询结果,搜索用时 15 毫秒
81.
82.
The venom of R. oxyrhynchus, a member of the psammophiine subfamily of the colubrid assemblage, was examined for biological activity using biochemical and pharmacological techniques. Venom displayed a high protein content, a complex electrophorectic profile and PLA2 activity but no detectable proteolytic or haematological activities. In the chick biventer cervicis nerve muscle preparation, venom (1-10 microg/ml) displayed postsynaptic neurotoxic activity as evidenced by inhibition of indirect (0.1 Hz, 0.2 ms, supramaximal V) twitches and responses to exogenous acetylcholine (1 mM) and carbachol (20 microM). This inhibitory effect was poorly reversible by washing. Venom (30-50 microg/ml) caused a rapid and readily reversible inhibition of direct (0.1 Hz, 2 ms, supramaximal V) twitches of the chick biventer cervicis nerve muscle preparation without morphological changes to the muscle fibers. Venom (30-100 microg/ml) inhibited electrically-evoked (0.2 Hz, 0.3 ms, 70-100 V) twitches of the prostatic segment of the rat vas deferens. This inhibitory effect was not significantly attenuated by 8-phenyltheophylline (8-PT; 20 microM), idazoxan (1 microM), a combination of ranitidine (0.2 microM) and thioperamide (10 microM) or capsazepine (10 microM). Venom (5 mg/kg) induced hypotension with subsequent cardiovascular collapse in the anaesthetised rat. The cardiovascular collapse was prevented by artificial respiration of the animals prior to venom administration. The biological activities demonstrated by R. oxyrhynchus venom may aid in prey envenomation strategies such as prey immobilisation. This study provides further evidence that colubrid venoms are comprised of multiple components which can display a variety of actions, some of which may be novel, therefore reinforcing the largely untapped potential of colubrid venoms. 相似文献
83.
Maria V Nesterova Natalie R Johnson Trina Stewart Scott Abrams Yoon S Cho-Chung 《Clinical cancer research》2005,11(16):5950-5955
84.
85.
Kieran Shay Struebin Abbotts Taylor Russell Ewell Hannah Michelle Butterklee Matthew Charles Bomar Natalie Akagi Gregory P. Dooley Christopher Bell 《Nutrients》2022,14(10)
Cannabidiol (CBD) is widely available and marketed as having therapeutic properties. Over-the-counter CBD is unregulated, many of the therapeutic claims lack scientific support, and controversy exists as to the safety of CBD-liver interaction. The study aims were to compare the pharmacokinetics of commercial CBD and CBD metabolites following the ingestion of five different CBD formulations, determine the influence of CBD on food induced thermogenesis, determine the influence of food on CBD pharmacokinetics, and determine the influence of CBD on markers of liver function. Fourteen males (body mass index ≥ 25 kg/m2) were studied in a placebo-controlled, randomized, crossover design. On five occasions, different CBD formulations were ingested (one per visit). On two additional occasions, CBD or placebo was ingested following a meal. CBD servings were standardized to 30 mg. Considerable pharmacokinetic variability existed between formulations; this pharmacokinetic variability transferred to several of the metabolites. CBD did not influence food induced thermogenesis but did favorably modify early insulin and triglyceride responses. Food appreciably altered the pharmacokinetics of CBD. Finally, CBD did not evoke physiologically relevant changes in markers of liver function. Collectively, these data suggest that consumers should be aware of the appreciable pharmacokinetic differences between commercial CBD formulations, CBD is unlikely to influence the caloric cost of eating but may prove to be of some benefit to initial metabolic responses, consuming CBD with food alters the dynamics of CBD metabolism and increases systemic availability, and low-dose CBD probably does not represent a risk to normal liver function. 相似文献
86.
Dorothee Bienzle Joyce Rousseau David Marom Jennifer MacNicol Linda Jacobson Stephanie Sparling Natalie Prystajecky Erin Fraser J. Scott Weese 《Emerging infectious diseases》2022,28(6):1154
We tested swab specimens from pets in households in Ontario, Canada, with human COVID-19 cases by quantitative PCR for SARS-CoV-2 and surveyed pet owners for risk factors associated with infection and seropositivity. We tested serum samples for spike protein IgG and IgM in household pets and also in animals from shelters and low-cost neuter clinics. Among household pets, 2% (1/49) of swab specimens from dogs and 7.7% (5/65) from cats were PCR positive, but 41% of dog serum samples and 52% of cat serum samples were positive for SARS-CoV-2 IgG or IgM. The likelihood of SARS-CoV-2 seropositivity in pet samples was higher for cats but not dogs that slept on owners’ beds and for dogs and cats that contracted a new illness. Seropositivity in neuter-clinic samples was 16% (35/221); in shelter samples, 9.3% (7/75). Our findings indicate a high likelihood for pets in households of humans with COVID-19 to seroconvert and become ill. 相似文献
87.
Chongliang Luo Md Nazmul Islam Natalie E Sheils John Buresh Martijn J Schuemie Jalpa A Doshi Rachel M Werner David A Asch Yong Chen 《J Am Med Inform Assoc》2022,29(8):1366
ObjectiveTo develop a lossless distributed algorithm for generalized linear mixed model (GLMM) with application to privacy-preserving hospital profiling.Materials and MethodsThe GLMM is often fitted to implement hospital profiling, using clinical or administrative claims data. Due to individual patient data (IPD) privacy regulations and the computational complexity of GLMM, a distributed algorithm for hospital profiling is needed. We develop a novel distributed penalized quasi-likelihood (dPQL) algorithm to fit GLMM when only aggregated data, rather than IPD, can be shared across hospitals. We also show that the standardized mortality rates, which are often reported as the results of hospital profiling, can also be calculated distributively without sharing IPD. We demonstrate the applicability of the proposed dPQL algorithm by ranking 929 hospitals for coronavirus disease 2019 (COVID-19) mortality or referral to hospice that have been previously studied.ResultsThe proposed dPQL algorithm is mathematically proven to be lossless, that is, it obtains identical results as if IPD were pooled from all hospitals. In the example of hospital profiling regarding COVID-19 mortality, the dPQL algorithm reached convergence with only 5 iterations, and the estimation of fixed effects, random effects, and mortality rates were identical to that of the PQL from pooled data.ConclusionThe dPQL algorithm is lossless, privacy-preserving and fast-converging for fitting GLMM. It provides an extremely suitable and convenient distributed approach for hospital profiling. 相似文献
88.
Marielle E. Yohe Christine M. Heske Elizabeth Stewart Peter C. Adamson Nabil Ahmed Cristina R. Antonescu Eleanor Chen Natalie Collins Alan Ehrlich Rene L. Galindo Berkley E. Gryder Heidi Hahn Sharon Hammond Mark E. Hatley Douglas S. Hawkins Madeline N. Hayes Andrea Hayes‐Jordan Lee J. Helman Simone Hettmer Myron S. Ignatius Charles Keller Javed Khan David G. Kirsch Corinne M. Linardic Philip J. Lupo Rossella Rota Jack F. Shern Janet Shipley Sivasish Sindiri Stephen J. Tapscott Christopher R. Vakoc Leonard H. Wexler David M. Langenau 《Pediatric blood & cancer》2019,66(10)
Overall survival rates for pediatric patients with high‐risk or relapsed rhabdomyosarcoma (RMS) have not improved significantly since the 1980s. Recent studies have identified a number of targetable vulnerabilities in RMS, but these discoveries have infrequently translated into clinical trials. We propose streamlining the process by which agents are selected for clinical evaluation in RMS. We believe that strong consideration should be given to the development of combination therapies that add biologically targeted agents to conventional cytotoxic drugs. One example of this type of combination is the addition of the WEE1 inhibitor AZD1775 to the conventional cytotoxic chemotherapeutics, vincristine and irinotecan. 相似文献
89.
Natalie M. G. M. Appels Maria J. Bolijn Maria A. J. van Eijndhoven Trevor C. Stephens Jos H. Beijnen Jan H. M. Schellens 《Cancer chemotherapy and pharmacology》2011,67(1):137-145
Purpose
AZD3409 is a novel DPTI that has potent activity against both FTase and GGTase-1. The in vitro inhibition profile of AZD3409 was characterized using three different cell lines: mouse embryogenic fibroblasts, transfected with H-RasV12 (MEF), A549 cells (Ki4B-Ras mutation) and MCF-7 cells (no Ras mutation).Methods
Both cytotoxicity and levels of inhibition of farnesylation and geranylgeranylation were determined in different assays in relation to the concentration of AZD3409. Results were compared with those obtained with the first-generation FTase inhibitor lonafarnib or the GGTase-1 inhibitor GGTI-2147.Results
The mean IC50 for cytotoxicity of AZD3409 and lonafarnib was 510 and 15,200?nM in MEF cells, 10,600 and 2,740?nM in A549 cells and 6,170 and 9,490?nM in MCF7 cells, respectively. In these cells, the IC50 for FTase activity of AZD3409 ranged from 3.0 to 14.2?nM and of lonafarnib from 0.26 to 31.3?nM. The inhibiting activity of AZD3409 and lonafarnib on general protein farnesylation was comparable with the specific farnesylation levels of HDJ-2. In vitro geranylgeranylation of Rap1a could be inhibited by GGTI-2147 in all three cell lines, but only in MCF-7 cells by AZD3409. These results are in agreement with the IC50 values for GGTase-1 activity as the lowest IC50 for AZD3409 was found in the MCF-7 cell line.Conclusions
AZD3409 inhibits farnesylation to a higher extent than geranylgeranylation. Both inhibition of farnesylation and geranylgeranylation could not be correlated to the antiproliferative activity of the drug. 相似文献90.
Macrocephaly-cutis marmorata telangiectatica congenita was first identified as a distinct syndrome in 1997. Since then there have been more than 10 further reports of the condition, several also comprising reviews of the earlier literature. Virtually all reported patients, however, are young children, and there is very little information about the natural evolution of the condition in adolescence and later life. This report describes a patient with features of macrocephaly-cutis marmorata telangiectatica congenita, though mildly affected, and her progression into teenage life. Her mild problems, many of which have largely resolved, demonstrate a possible more optimistic view of the condition than is currently held. The difficulties in making the diagnosis in an adult patient are also discussed. 相似文献